SIGA Technologies Inc. - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company primarily focused on the sale of its lead product, TPOXX® (tecovirimat), an antiviral drug for the treatment of smallpox. The company operates in a single segment, deriving revenue mainly from contracts with the U.S. Government (BARDA and DoD) and international governments. As of October 24, 2025, the company had 71,611,302 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $2.62 million | $10.01 million | $90.78 million | $57.25 million |
| Net Income (Loss) | $(6.37) million | $1.34 million | $28.71 million | $13.45 million |
| Operating Income (Loss) | $(10.22) million | $0.54 million | $33.20 million | $12.90 million |
| Cash and Equivalents | $171.96 million (as of Sept 30, 2025) | |||
| Operating Cash Flow (YTD) | $60.33 million | $(7.55) million | ||
| Dividends Paid (YTD) | $43.03 million | $42.67 million |
Material Changes vs. Prior Period
- Revenue Volatility: Q3 2025 revenue ($2.62M) decreased significantly compared to Q3 2024 ($10.01M) due to the absence of large point-in-time product deliveries in the current quarter. However, YTD 2025 revenue ($90.78M) increased 58% compared to YTD 2024 ($57.25M), driven by $79.1M in product delivery revenue recognized in the first two quarters of 2025.
- Profitability: The company reported a net loss of $6.37M for Q3 2025, contrasting with a net income of $1.34M in Q3 2024. This quarterly loss was driven by higher R&D expenses ($7.05M vs $3.02M) and lower revenue. Conversely, YTD 2025 net income of $28.71M more than doubled the YTD 2024 figure of $13.45M.
- Expense Increases: R&D expenses rose $4.1M in Q3 and $5.9M YTD compared to the prior year, attributed to increased self-funded research, IT enhancements, and headcount growth. SG&A expenses decreased YTD by $2.3M due to lower international promotion fees and one-time compensation costs in 2024.
- Liquidity: Cash and cash equivalents increased by $16.6M during the nine months ended September 30, 2025, despite the payment of a $43.0M special dividend, supported by strong operating cash flow of $60.3M.
Guidance, Outlook, and Risks
- Regulatory Risks (Mpox): The EMA initiated a referral procedure for Tecovirimat-SIGA following questions regarding its effectiveness in treating mpox, based on results from the PALM007, STOMP, and UNITY clinical trials which did not meet primary endpoints for lesion resolution. The MHRA reassessment is ongoing. This poses a risk to international marketing authorizations.
- Government Shutdown Risk: The filing highlights that an extended U.S. government shutdown could materially adversely affect business by delaying funding decisions, contract awards, and ongoing work under existing contracts.
- Contract Outlook: The 19C BARDA contract contemplates up to $630 million in payments. As of September 30, 2025, $545.2 million in options have been exercised. The company expects to recognize revenue from current performance obligations over the next 12 months (product) and three years (R&D).
- Tax Law Changes: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 restored immediate expensing for domestic R&D and 100% bonus depreciation, impacting the effective tax rate (25.1% YTD 2025 vs 23.1% YTD 2024).
- Dividend Policy: The company paid a special dividend of $0.60 per share in May 2025, totaling approximately $43 million.
Investor Verification Checklist
- Verify the status of the EMA and MHRA reassessments regarding Tecovirimat-SIGA's mpox indication and potential impact on international sales.
- Monitor the timeline for the Supplemental NDA submission for smallpox post-exposure prophylaxis (PEP), currently targeted for 2026.
- Assess the impact of potential U.S. government shutdowns on the timing of BARDA contract payments and deliveries.
- Review the composition of the $12.5 million in outstanding purchase commitments for manufacturing obligations.
- Confirm the sustainability of the dividend policy given the company's cash burn on self-funded R&D and the cyclical nature of government contract revenue recognition.